Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14C AZD4831 · 1 trial · 1 indication
Assessment of the total radioactivity by measuring the cumulative amount of AZD4831 excreted (CumAe)
Assessment of the total radioactivity by measuring the cumulative amount of AZD4831 excreted and expressed as a percentage of the administered dose (CumFe)
Assessment of metabolites and structural identification by AMS analysis
Assessment of metabolites and structural identification by AMS analysis
Assessment of metabolites and structural identification by AMS analysis
| Arm | Type | Description |
|---|---|---|
| [14C]AZD4831 Oral Solution | EXPERIMENTAL | One 10 mg dose of \[14C\]AZD4831 Oral Solution |
| Name | Type | Description |
|---|---|---|
| 14C]AZD4831 Oral Solution | DRUG | 10 mg dose of \[14C\]AZD4831 Oral Solution |
Inclusion Criteria: 1. Provision of signed and dated written informed consent prior to any study specific procedures. 2. Healthy male subjects aged 18 to 65 years inclusive at the time of signing informed consent with suitable veins for cannulation or repeated venepuncture. 3. Body mass index (BMI)...
14C AZD4831 is an investigational small molecule being studied for cardiovascular disease. It is a radiolabeled form of the drug, used in a Phase 1 clinical trial to assess mass balance recovery, pharmacokinetics, metabolite profile, and metabolite identification. The drug is still in clinical development and is not approved.
14C AZD4831 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting clinical research on this investigational drug for cardiovascular disease.
14C AZD4831 is in Phase 1 clinical development. The drug is investigational and has not been approved. One Phase 1 trial has been completed, and the drug is not currently in active trials.
14C AZD4831 has one completed clinical trial, NCT04407091, titled "A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831." This Phase 1 study enrolled 8 male healthy volunteers in the United Kingdom.
14C AZD4831 is a radiolabeled version of the drug AZD4831, where the carbon-14 isotope is incorporated for research purposes. This labeling allows researchers to track the drug's absorption, distribution, metabolism, and excretion in the body during clinical studies.